協和キリンの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2019/02/20 | 2,146 | 2,168 | 2,133 | 2,145 | -1 | ±0% | 1,050,600 |
2019/02/19 | 2,153 | 2,156 | 2,139 | 2,146 | -3 | -0.1% | 705,200 |
2019/02/18 | 2,164 | 2,175 | 2,140 | 2,149 | +16 | +0.8% | 835,100 |
2019/02/15 | 2,160 | 2,177 | 2,122 | 2,133 | +5 | +0.2% | 1,287,700 |
2019/02/14 | 2,135 | 2,148 | 2,116 | 2,128 | -47 | -2.2% | 778,900 |
2019/02/13 | 2,175 | 2,198 | 2,164 | 2,175 | +31 | +1.4% | 1,127,200 |
2019/02/12 | 2,130 | 2,169 | 2,121 | 2,144 | +14 | +0.7% | 1,362,300 |
2019/02/08 | 2,167 | 2,207 | 2,128 | 2,130 | -28 | -1.3% | 1,830,000 |
2019/02/07 | 2,201 | 2,215 | 2,136 | 2,158 | -77 | -3.4% | 1,045,900 |
2019/02/06 | 2,201 | 2,273 | 2,185 | 2,235 | +124 | +5.9% | 2,590,900 |
2019/02/05 | 2,136 | 2,160 | 2,094 | 2,111 | -2 | -0.1% | 1,216,100 |
2019/02/04 | 2,108 | 2,137 | 2,103 | 2,113 | +29 | +1.4% | 880,500 |
2019/02/01 | 2,081 | 2,106 | 2,073 | 2,084 | +4 | +0.2% | 611,200 |
2019/01/31 | 2,097 | 2,099 | 2,067 | 2,080 | +23 | +1.1% | 957,000 |
2019/01/30 | 2,093 | 2,098 | 2,052 | 2,057 | -47 | -2.2% | 1,089,100 |
2019/01/29 | 2,050 | 2,105 | 2,048 | 2,104 | +38 | +1.8% | 881,800 |
2019/01/28 | 2,052 | 2,072 | 2,033 | 2,066 | ±0 | ±0% | 872,600 |
2019/01/25 | 2,100 | 2,109 | 2,066 | 2,066 | -44 | -2.1% | 1,170,700 |
2019/01/24 | 2,100 | 2,110 | 2,075 | 2,110 | +12 | +0.6% | 903,600 |
2019/01/23 | 2,105 | 2,105 | 2,075 | 2,098 | -26 | -1.2% | 988,200 |
2019/01/22 | 2,134 | 2,160 | 2,119 | 2,124 | +18 | +0.9% | 868,700 |
2019/01/21 | 2,128 | 2,130 | 2,093 | 2,106 | -10 | -0.5% | 918,700 |
2019/01/18 | 2,120 | 2,140 | 2,111 | 2,116 | +1 | ±0% | 771,000 |
2019/01/17 | 2,128 | 2,156 | 2,103 | 2,115 | -10 | -0.5% | 904,700 |
2019/01/16 | 2,120 | 2,148 | 2,108 | 2,125 | +21 | +1% | 1,076,900 |
2019/01/15 | 2,090 | 2,133 | 2,088 | 2,104 | -26 | -1.2% | 1,175,500 |
2019/01/11 | 2,163 | 2,173 | 2,107 | 2,130 | -35 | -1.6% | 1,735,800 |
2019/01/10 | 2,147 | 2,169 | 2,131 | 2,165 | +20 | +0.9% | 1,192,700 |
2019/01/09 | 2,133 | 2,169 | 2,102 | 2,145 | ±0 | ±0% | 1,373,900 |
2019/01/08 | 2,145 | 2,176 | 2,117 | 2,145 | +18 | +0.8% | 1,261,400 |
2019/01/07 | 2,182 | 2,199 | 2,113 | 2,127 | -5 | -0.2% | 1,045,800 |
2019/01/04 | 2,027 | 2,138 | 2,027 | 2,132 | +55 | +2.6% | 1,491,000 |
2018/12/28 | 2,107 | 2,114 | 2,057 | 2,077 | -52 | -2.4% | 934,200 |
2018/12/27 | 2,095 | 2,150 | 2,082 | 2,129 | +84 | +4.1% | 1,590,000 |
2018/12/26 | 2,000 | 2,050 | 1,998 | 2,045 | +59 | +3% | 1,440,100 |
2018/12/25 | 2,070 | 2,078 | 1,967 | 1,986 | -124 | -5.9% | 1,039,800 |
2018/12/21 | 2,145 | 2,152 | 2,104 | 2,110 | -45 | -2.1% | 1,252,900 |
2018/12/20 | 2,203 | 2,232 | 2,146 | 2,155 | -78 | -3.5% | 1,102,500 |
2018/12/19 | 2,237 | 2,264 | 2,222 | 2,233 | -3 | -0.1% | 788,400 |
2018/12/18 | 2,261 | 2,282 | 2,234 | 2,236 | -55 | -2.4% | 1,088,800 |
2018/12/17 | 2,279 | 2,300 | 2,266 | 2,291 | +8 | +0.4% | 633,400 |
2018/12/14 | 2,281 | 2,330 | 2,278 | 2,283 | -3 | -0.1% | 1,747,900 |
2018/12/13 | 2,285 | 2,294 | 2,253 | 2,286 | -4 | -0.2% | 823,400 |
2018/12/12 | 2,263 | 2,294 | 2,255 | 2,290 | +45 | +2% | 1,045,800 |
2018/12/11 | 2,259 | 2,267 | 2,241 | 2,245 | -4 | -0.2% | 881,800 |
2018/12/10 | 2,270 | 2,276 | 2,233 | 2,249 | -74 | -3.2% | 908,100 |
2018/12/07 | 2,310 | 2,337 | 2,304 | 2,323 | +27 | +1.2% | 876,300 |
2018/12/06 | 2,321 | 2,344 | 2,279 | 2,296 | -44 | -1.9% | 1,317,000 |
2018/12/05 | 2,246 | 2,345 | 2,244 | 2,340 | +71 | +3.1% | 1,138,600 |
2018/12/04 | 2,297 | 2,318 | 2,264 | 2,269 | -40 | -1.7% | 825,700 |
1501~
1550
件表示中 / 3680件
類似銘柄と比較する
現在ご覧いただいている「協和キリン」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
協和キリン | 216,800円 | -3.5% | -11.3% | 2.77% | 19.91倍 | 1.33倍 |
|
キリン傘下。医薬品、バイオが主力。独自の抗体高活性化技術に強み。富士フイルムと提携 |
アステラス薬 | 133,700円 | +18.5% | -96.0% | 5.53% | 170.97倍 | 1.56倍 |
|
医薬品国内2位。開発技術起点の研究開発体制。前立腺がん薬が柱。遺伝子・細胞治療技術育成 |
塩野義 | 228,500円 | +5.7% | +3.9% | 2.51% | 11.37倍 | 1.50倍 |
|
抗HIV薬が大型製品に。感染症、疼痛・中枢神経領域に強み。米国に積極展開。欧州、アジア開拓 |
エーザイ | 372,700円 | +1.7% | -2.9% | 4.29% | 24.45倍 | 1.28倍 |
|
神経系、がん領域に強み。認知症薬は米バイオジェンと、抗がん薬では米メルクと国際協業推進 |
小野薬 | 171,900円 | -3.5% | -50.2% | 4.65% | 13.93倍 | 1.03倍 |
|
医療用医薬品専業の中堅。自社開発品多い。先駆的がん免疫阻害剤「オプジーボ」が成長牽引 |
市場注目の銘柄
チャート関連のコラム